Relapsed Primary Central Nervous System Lymphoma
3 clinical trials · Condition
◉ Watch Relapsed Primary Central Nervous System Lymphoma
| Record | Firm | Date |
|---|---|---|
| A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT04845139) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-07-02 |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) (NCT03328078) | Curis, Inc. | 2017-12-28 |
Track Relapsed Primary Central Nervous System Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.